Provided are an inhibitor of PI4KIIIα/FAM126/TTC7 complex and a method that uses the inhibitor to prevent or treat mood disorders.

Provided are an inhibitor of PI4KIIIα/FAM126/TTC7 complex and a method that uses the inhibitor to prevent or treat mood disorders.

Presently provided are indoximod prodrug and salt compounds and pharmaceutical compositions comprising salts and prodrugs of indoximod, that produce enhanced plasma concentration and exposure to indoximod compared to direct administration of indoximod, in patients in need of treatment of immunosuppression mediated by the indoleamine-2,3-dioxygenase pathway, such as patients with cancer or chronic infectious diseases.

Presently provided are indoximod prodrug and salt compounds and pharmaceutical compositions comprising salts and prodrugs of indoximod, that produce enhanced plasma concentration and exposure to indoximod compared to direct administration of indoximod, in patients in need of treatment of immunosuppression mediated by the indoleamine-2,3-dioxygenase pathway, such as patients with cancer or chronic infectious diseases.

Disclosed is a pharmaceutical composition comprising a micromolecule PI4KIIIα inhibitor and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier comprises a lipid. Also disclosed are a method for preparing the pharmaceutical composition, and a method for treating PI4KIIIα-related diseases by using the pharmaceutical composition.

Disclosed is a pharmaceutical composition comprising a micromolecule PI4KIIIα inhibitor and a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier comprises a lipid. Also disclosed are a method for preparing the pharmaceutical composition, and a method for treating PI4KIIIα-related diseases by using the pharmaceutical composition.

The present invention provides a betaine compound for use in the prevention of obesity, excessive fat accumulation and/or metabolic disorders associated with either of the foregoing in a subject, wherein the prevention comprises administering the betaine compound directly to the subject during infancy or, alternatively, to the subject's mother during breast-feeding. Also provided are compositions comprising an effective amount of betaine compound together with one or more pharmaceutically or edible acceptable excipients and/or carriers for this use.

The invention relates to a process for identifying procoagulant platelets both in vitro and in vivo, and the identification of compounds which selectively inhibit formation of procoagulant platelets.

The invention relates to a process for identifying procoagulant platelets both in vitro and in vivo, and the identification of compounds which selectively inhibit formation of procoagulant platelets.

The present invention relates to synergistic pharmaceutical combinations comprising organic arsenoxide compounds and mTOR inhibitors. Further, the present invention relates to the use of these pharmaceutical combinations in therapy, in particular, treatment of proliferative diseases.